ES2323301T3 - Derivados de triazolo 4,5-d pirimidina y su uso como antagonistas del receptor purinergico. - Google Patents
Derivados de triazolo 4,5-d pirimidina y su uso como antagonistas del receptor purinergico. Download PDFInfo
- Publication number
- ES2323301T3 ES2323301T3 ES02729452T ES02729452T ES2323301T3 ES 2323301 T3 ES2323301 T3 ES 2323301T3 ES 02729452 T ES02729452 T ES 02729452T ES 02729452 T ES02729452 T ES 02729452T ES 2323301 T3 ES2323301 T3 ES 2323301T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- group
- mono
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000001696 purinergic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- -1 aryloxycarbonylaryl Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- 125000005000 thioaryl group Chemical group 0.000 abstract 2
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 1
- 125000006550 alkoxycarbonyl aryl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 abstract 1
- 125000005325 aryloxy aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 150000001540 azides Chemical class 0.000 abstract 1
- 125000004069 aziridinyl group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004623 carbolinyl group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000005026 carboxyaryl group Chemical group 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005027 hydroxyaryl group Chemical group 0.000 abstract 1
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 abstract 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000005936 piperidyl group Chemical group 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El uso de un compuesto de la fórmula (I):**(Ver fórmula)** donde R1 se elige entre H, alquilo, arilo, alcoxi, ariloxi, alquiltio, ariltio, halógeno, CN, NR5R6, NR4COR5, NR4CONR5 R6, NR4CO2R7 y NR4SO2R7; R2 se elige entre radicales arilo unidos mediante un carbono insaturado; R3 se elige entre H, alquilo, COR5, CO2R7, CONR5R6, CONR4NR5R6 y SO2R7; R4, R5 y R6 se eligen independientemente entre H, alquilo y arilo, o cuando R5 y R6 están en un grupo NR5R6, R5 y R6 pueden estar unidos formando un grupo heterocíclico, o si R4, R5 y R6 están en un grupo (CONR4NR5R6), R4 y R5 pueden estar unidos formando un grupo heterocíclico; y R7 se escoge entre alquilo y arilo, cuando cualquiera de los radicales R1 a R7 está escogido entre alquilo, alcoxi y tioalquilo, este grupo alquilo o el grupo alquilo del grupo alcoxi o tioalquilo puede ir sustituido o no, y cuando cualquiera de los radicales R1 a R7 está elegido entre arilo, ariloxi y tioarilo, dicho grupo arilo o el grupo arilo del grupo ariloxi o tioarilo puede ir sustituido o no, y cuando R5 y R6, o R4 y R5, están unidos formando un grupo heterocíclico, éste puede estar sustituido o no, y los sustituyentes se escogen entre alquilo, arilo, arilalquilo; átomos de halógeno, haloalquilo, haloarilo; grupos que llevan oxígeno seleccionados entre hidroxilo, hidroxialquilo, hidroxiarilo, (aril)(hidroxi)alquilo, alcoxi, ariloxi, alcoxialquilo, ariloxialquilo, alcoxiarilo, ariloxiarilo, carboxaldehído, alquilcarbonilo, arilcarbonilo, alquilcarbonilalquilo, alquilcarbonilarilo, arilcarbonilalquilo, arilcarbonilarilo, arilalquilcarbonilo, arilalquilcarbo-nilalquilo, arilalquilcarbonilarilo, carboxilo, carboxialquilo, carboxiarilo, alcoxicarbonilo, ariloxicarbonilo, alco-xicarbonilalquilo, ariloxicarbonilalquilo, alcoxicarbonilarilo, ariloxicarbonilarilo, alquilcarboniloxi, alquilcarbo-niloxialquilo, aminocarbonilo, mono- o di-alquil-aminocarbonilo, aminocarbonilo cíclico, aminocarbonilalquilo, mono- o di-alquilaminocarbonilalquilo, arilaminocarbonilo o arilalquilaminocarbonilo, alquilcarbonilamino, aril-carbonilamino o arilalquilcarbonilamino, alcoxicarbonilamino, ariloxicarbonilamino, arilalquiloxicarbonilamino, aminocarboniloxi, mono- o di-alquilamino-carboniloxi, arilaminocarboniloxi o arilalquilaminocarboniloxi, mono-o di-alquilaminocarbonilamino, arilaminocarbonilamino o arilalquilaminocarbonilamino; grupos que llevan nitrógeno seleccionados entre amino, mono- o dialquilamino, amino cíclico, arilamino, aminoalquilo, mono- o di-alquilaminoalquilo, azidas, ciano, cianoalquilo, nitro, aminosulfonilo, mono- o di-alquilamino-sulfonilo, mono- o di-arilaminosulfonilo, alquil- o aril-sulfonilamino, alquil- o aril-sulfonil(alquil)-amino, alquil- o aril-sulfonil(aril) amino; grupos que llevan azufre seleccionados entre alquiltio, alquilsulfinilo, alquilsulfonilo, alquiltioalquilo, alquilsulfinilalquilo, alquilsulfonilalquilo, ariltio, arilsulfinilo, arilsulfonilo, ariltioalquilo, arilsulfinilalquilo, arilsul-fonilalquilo; y grupos heterocíclicos escogidos entre tienilo, furanilo, pirrolilo, imidazolilo, pirazolilo, tiazolilo, isotiazolilo, oxazolilo, oxadiazolilo, tiadiazolilo, aziridinilo, azetidinilo, pirrolidinilo, pirrolinilo, imidazolidinilo, imidazolinilo, pirazolidinilo, tetrahidrofuranilo, piranilo, pironilo, piridilo, pirazinilo, piridazinilo, piperidilo, hexahidroazepinilo, piperazinilo, morfolinilo, tianaftilo, benzofuranilo, isobenzofuranilo, indolilo, oxiindolilo, isoindolilo, indazolilo, indolinilo, 7-azaindolilo, benzopiranilo, cumarinilo, isocumarinilo, quinolinilo, isoquinolinilo, naftridinilo, cinnolinilo, quinazolinilo, piridopiridilo, benzoxazinilo, quinoxalinilo, cromenilo, cromanilo, isocromanilo, ftalazinilo y carbolinilo, donde los grupos alquilo están seleccionados entre radicales hidrocarbilo C3 a C12 cíclicos y C1 a C10 acíclicos, ramificados y lineales, saturados e insaturados;
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0100624 | 2001-01-10 | ||
| GBGB0100624.6A GB0100624D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds VII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2323301T3 true ES2323301T3 (es) | 2009-07-13 |
Family
ID=9906571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02729452T Expired - Lifetime ES2323301T3 (es) | 2001-01-10 | 2002-01-10 | Derivados de triazolo 4,5-d pirimidina y su uso como antagonistas del receptor purinergico. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7141575B2 (es) |
| EP (1) | EP1392312B1 (es) |
| JP (2) | JP4287146B2 (es) |
| KR (1) | KR100913845B1 (es) |
| CN (3) | CN1496262A (es) |
| AT (1) | ATE424207T1 (es) |
| AU (1) | AU2002219355B2 (es) |
| BR (1) | BR0206559A (es) |
| CA (1) | CA2433453C (es) |
| CZ (1) | CZ301916B6 (es) |
| DE (1) | DE60231394D1 (es) |
| DK (1) | DK1392312T3 (es) |
| ES (1) | ES2323301T3 (es) |
| GB (1) | GB0100624D0 (es) |
| HR (1) | HRP20030533A2 (es) |
| HU (1) | HUP0401047A3 (es) |
| IL (2) | IL156713A0 (es) |
| MX (1) | MXPA03006165A (es) |
| NO (1) | NO328475B1 (es) |
| NZ (1) | NZ527248A (es) |
| PL (1) | PL363101A1 (es) |
| PT (1) | PT1392312E (es) |
| RS (1) | RS51121B (es) |
| RU (1) | RU2317084C2 (es) |
| WO (1) | WO2002055083A1 (es) |
| ZA (1) | ZA200305087B (es) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
| AU2003304527B2 (en) * | 2002-12-19 | 2010-09-09 | Merck Sharp & Dohme Corp. | Uses of adenosine A2a receptor antagonists |
| EP1622912B1 (en) | 2003-04-23 | 2009-05-27 | Schering Corporation | 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists |
| NZ546611A (en) * | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| KR20060135901A (ko) | 2004-04-21 | 2006-12-29 | 쉐링 코포레이션 | 피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]피리미딘아데노신 Ａ2ａ 수용체 길항제 |
| US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
| CN100398542C (zh) * | 2005-03-18 | 2008-07-02 | 北京大学 | 具有抗hiv活性的取代1,2,3-三唑并嘧啶新化合物，制备方法及用途 |
| BRPI0609509A2 (pt) | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
| US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
| EP1902716A4 (en) * | 2005-06-07 | 2009-05-13 | Kyowa Hakko Kirin Co Ltd | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING |
| CA2617817C (en) * | 2005-08-02 | 2014-05-27 | Kyowa Kirin Co., Ltd. | Thiazole derivatives for treating or preventing sleep disorders |
| CA2622741A1 (en) | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists |
| US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| PE20070521A1 (es) | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
| DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| US20080027079A1 (en) * | 2006-06-22 | 2008-01-31 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| WO2008086201A1 (en) * | 2007-01-05 | 2008-07-17 | Biogen Idec Ma Inc. | Polymorphs and solvates of a pharmaceutical and methods of making |
| EP2117313A4 (en) * | 2007-01-12 | 2011-04-27 | Biogen Idec Inc | PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM |
| FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| FR2915199B1 (fr) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| AU2009222047A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
| US8415353B2 (en) | 2008-03-04 | 2013-04-09 | Merck Sharp & Dohme Corp. | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| WO2009152521A2 (en) * | 2008-06-13 | 2009-12-17 | Parkinson's Institute | Diagnosis of neurodegenerative disorders |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| JP5599311B2 (ja) * | 2008-07-23 | 2014-10-01 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
| TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| WO2011050160A1 (en) * | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
| US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
| DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
| AU2016379425B2 (en) | 2015-12-24 | 2021-11-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| CN107021963A (zh) * | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| US20190358262A1 (en) | 2016-12-03 | 2019-11-28 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| CN106883191A (zh) * | 2017-01-19 | 2017-06-23 | 华侨大学 | 一种n‑取代苯并三氮唑衍生物的制备方法 |
| US11066413B2 (en) * | 2017-03-07 | 2021-07-20 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
| WO2018183965A1 (en) * | 2017-03-30 | 2018-10-04 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo[4,5d] pyramidine derivatives and intermediates thereof |
| WO2018187484A1 (en) | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| CN111225675B (zh) | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| EP3644721A1 (en) | 2017-06-29 | 2020-05-06 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019123482A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| IL275817B2 (en) | 2018-01-04 | 2024-04-01 | Impetis Biosciences Ltd | Tricyclic compounds, compositions and medicinal applications thereof |
| IL279688B2 (en) * | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| CA3106041A1 (en) | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| JP2021531751A (ja) | 2018-07-12 | 2021-11-25 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシン経路活性化を有する癌を検出および治療するための方法 |
| WO2020068583A1 (en) * | 2018-09-27 | 2020-04-02 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof |
| MX2021005022A (es) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d). |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| EP3880238A1 (en) | 2018-11-16 | 2021-09-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| BR112021010354A2 (pt) | 2018-11-30 | 2021-11-03 | Juno Therapeutics Inc | Métodos para o tratamento usando terapia celular adotiva |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CN110251518A (zh) * | 2019-06-28 | 2019-09-20 | 青岛科技大学 | 1,2,4-三氮唑类杂环化合物在制备预防或治疗与中枢系统相关疾病药物中的应用 |
| CN112479956A (zh) | 2019-07-30 | 2021-03-12 | 杭州阿诺生物医药科技有限公司 | 一种用于制备腺苷受体抑制剂中间体的方法 |
| CN112608330B (zh) | 2019-07-30 | 2021-09-28 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体抑制剂 |
| WO2021050688A1 (en) * | 2019-09-10 | 2021-03-18 | X-Chem, Inc. | Compounds and uses thereof |
| KR20220066332A (ko) * | 2019-10-22 | 2022-05-24 | 알파라 컴퍼니 리미티드 | 피리미딘 아미드 화합물 및 이의 용도 |
| KR20210061202A (ko) | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
| CN116589464B (zh) * | 2022-02-14 | 2025-10-31 | 上海科技大学 | 嘧啶并环类化合物、其制备方法和应用 |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| CN120051298A (zh) | 2022-08-05 | 2025-05-27 | 朱诺治疗学股份有限公司 | Gprc5d和bcma特异性嵌合抗原受体 |
| WO2024129778A2 (en) | 2022-12-13 | 2024-06-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56131586A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | Triazolopyrimidine derivative and its preparation |
| JPS56131587A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | 7-substituted triazolopyrimidine derivative and its preparation |
| JPS5962595A (ja) | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５，７―トリ置換―トリアゾロピリミジン誘導体 |
| DE3304330A1 (de) | 1983-02-09 | 1984-08-09 | Basf Ag, 6700 Ludwigshafen | Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung |
| JPS60140335A (ja) | 1983-12-28 | 1985-07-25 | Konishiroku Photo Ind Co Ltd | 熱現像カラ−感光材料 |
| US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
| US5194581A (en) | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
| IT1264901B1 (it) * | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| ATE208199T1 (de) * | 1993-07-27 | 2001-11-15 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen parkinsonsche krankheit |
| CA2174080A1 (en) | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| HU221880B1 (hu) | 1995-07-11 | 2003-02-28 | Astrazeneca Ab, | Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| RU2174518C2 (ru) * | 1995-07-11 | 2001-10-10 | Астра Фармасьютикалз Лтд. | Производные 3-н-1,2,3-триазоло-[4,5-d]пиримидина, фармацевтическая композиция и способ их получения |
| IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| TR199900389T2 (xx) * | 1996-08-28 | 2000-06-21 | Pfizer Inc. | �kame edilmi� 6,5-hetero-bisiklik t�revleri. |
| CA2284737C (en) * | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| US5912225A (en) * | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
| NZ501184A (en) * | 1997-04-30 | 2002-08-28 | Guilford Pharm Inc | Biodegradable poly (phosphodiester) compositions that degrade in vivo into non-toxic residues |
| IT1291372B1 (it) * | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6028163A (en) | 1997-06-27 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Solution polymerization of high molecular weight poly(phosphoesters) in toluene |
| CA2296014A1 (en) * | 1997-07-03 | 1999-01-14 | Frank W. Hobbs | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| TW530058B (en) * | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
| US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
| WO1999026627A1 (en) | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| CA2315736A1 (en) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| DE60022366T2 (de) | 1999-07-02 | 2006-06-14 | Eisai Co Ltd | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus |
-
2001
- 2001-01-10 GB GBGB0100624.6A patent/GB0100624D0/en not_active Ceased
-
2002
- 2002-01-10 EP EP02729452A patent/EP1392312B1/en not_active Expired - Lifetime
- 2002-01-10 DK DK02729452T patent/DK1392312T3/da active
- 2002-01-10 ZA ZA200305087A patent/ZA200305087B/xx unknown
- 2002-01-10 IL IL15671302A patent/IL156713A0/xx unknown
- 2002-01-10 BR BR0206559-2A patent/BR0206559A/pt not_active Application Discontinuation
- 2002-01-10 CA CA2433453A patent/CA2433453C/en not_active Expired - Lifetime
- 2002-01-10 HU HU0401047A patent/HUP0401047A3/hu unknown
- 2002-01-10 AT AT02729452T patent/ATE424207T1/de active
- 2002-01-10 HR HR20030533A patent/HRP20030533A2/hr not_active Application Discontinuation
- 2002-01-10 WO PCT/GB2002/000091 patent/WO2002055083A1/en not_active Ceased
- 2002-01-10 RS YUP-555/03A patent/RS51121B/sr unknown
- 2002-01-10 KR KR1020037009240A patent/KR100913845B1/ko not_active Expired - Fee Related
- 2002-01-10 JP JP2002555817A patent/JP4287146B2/ja not_active Expired - Lifetime
- 2002-01-10 DE DE60231394T patent/DE60231394D1/de not_active Expired - Lifetime
- 2002-01-10 AU AU2002219355A patent/AU2002219355B2/en not_active Ceased
- 2002-01-10 CN CNA028063031A patent/CN1496262A/zh active Pending
- 2002-01-10 CN CN200910164664A patent/CN101691370A/zh active Pending
- 2002-01-10 ES ES02729452T patent/ES2323301T3/es not_active Expired - Lifetime
- 2002-01-10 PT PT02729452T patent/PT1392312E/pt unknown
- 2002-01-10 PL PL02363101A patent/PL363101A1/xx not_active Application Discontinuation
- 2002-01-10 MX MXPA03006165A patent/MXPA03006165A/es active IP Right Grant
- 2002-01-10 CN CNA2008100024015A patent/CN101214248A/zh active Pending
- 2002-01-10 NZ NZ527248A patent/NZ527248A/en active IP Right Revival
- 2002-01-10 RU RU2003124651/04A patent/RU2317084C2/ru not_active IP Right Cessation
- 2002-01-10 US US10/250,942 patent/US7141575B2/en not_active Expired - Lifetime
- 2002-01-10 CZ CZ20031955A patent/CZ301916B6/cs not_active IP Right Cessation
-
2003
- 2003-06-30 IL IL156713A patent/IL156713A/en not_active IP Right Cessation
- 2003-07-09 NO NO20033146A patent/NO328475B1/no not_active IP Right Cessation
-
2006
- 2006-08-22 US US11/507,625 patent/US7405219B2/en not_active Expired - Lifetime
-
2007
- 2007-12-20 US US12/003,110 patent/US7589097B2/en not_active Expired - Lifetime
-
2008
- 2008-12-02 JP JP2008308004A patent/JP5202259B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040893A1 (es) | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA | |
| DE60228406D1 (de) | PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS | |
| MXPA05008619A (es) | Derivados novedosos de 2-piridincarboxamida. | |
| ES2322602T3 (es) | Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc. | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| MX2009013728A (es) | Derivados de bicicloanilina. | |
| NZ337529A (en) | Pyrrolo[2,3-d]pyrimidine derivatives useful as tyrosine kinase inhibitors | |
| HRP20110498T1 (hr) | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti | |
| MY163531A (en) | Aminopyrazole derivative | |
| HRP20090533T1 (hr) | Derivati indolila kao modulatori x-receptora | |
| PE20030808A1 (es) | Derivados triciclicos heterociclicos como antagonistas receptores de trombina | |
| DE602005003960D1 (en) | Oximesther-fotoinitiatoren | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| DK0767793T3 (da) | N-substituerede-(dihydroxyboryl)alkylderivater af purin, indol og pyrimidin, som er nyttige som inhibitorer af inflammatoriske cytokiner | |
| CO5320600A1 (es) | Agentes antibacterianos de 3-aminoquinazolin-2,4-dionas | |
| TR200100378T2 (tr) | P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç | |
| MX2009004442A (es) | Inhibidores de la proteina cinasa de serina-treonina ikk-beta. | |
| PL327073A1 (en) | Novel derivatives of indolo-2,3-diono-3-oxime | |
| SI1755606T2 (sl) | Derivati kinazolinona, ki so uporabni kot antagonisti vaniloidnih receptorjev | |
| MXPA02001473A (es) | Azaindoles que tienen afinidad con el receptor de serotonina. | |
| CO5140116A1 (es) | Compuestos espiro derivados de imidazo-benzazepina con actividad antihistaminica y sus procesos de obtencion a partir de sus intermediarios de sintesis | |
| ES2180201T3 (es) | Derivados de azetidinona para el tratamiento de infecciones por hcmv. | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| WO2009028387A1 (ja) | プロテアーゼ阻害剤耐性を有する癌の治療薬 | |
| NZ335252A (en) | Substituted 3-thia-1,2,3,4-tetrahydrocarbazole, 6,7,8,9-tetrahydropyrido[1,2-a]indole, 4,5-dihydro-thiopyrano[3,4-b]indole, pyrano[3,4-b]indole or beta-carbolinyl derivatives |